NEXGEL, Inc. (NXGL)
NASDAQ: NXGL · Real-Time Price · USD
0.6753
-0.0066 (-0.97%)
Mar 25, 2026, 4:00 PM EDT - Market closed
NEXGEL Employees
NEXGEL had 19 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
19
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$614,000
Profits / Employee
-$151,579
Market Cap
5.50M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 19 | 0 | - |
| Dec 31, 2023 | 19 | 7 | 58.33% |
| Dec 31, 2022 | 12 | 2 | 20.00% |
| Dec 31, 2021 | 10 | 2 | 25.00% |
| Dec 31, 2020 | 8 | 2 | 33.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Jin Medical International | 273 |
| Retractable Technologies | 227 |
| Bionano Genomics | 100 |
| Precision Optics Corporation | 90 |
| Femasys | 71 |
| Ekso Bionics Holdings | 55 |
| Nephros | 36 |
| Milestone Scientific | 17 |
NXGL News
- 13 days ago - NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products - GlobeNewsWire
- 15 days ago - NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products - GlobeNewsWire
- 15 days ago - EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue - Benzinga
- 3 months ago - NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx - GlobeNewsWire
- 4 months ago - NEXGEL Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 8 months ago - NEXGEL to Report Second Quarter 2025 Financial Results on August 12th - GlobeNewsWire
- 8 months ago - NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement - GlobeNewsWire
- 9 months ago - NEXGEL and STADA AG Announce Expansion of Partnership for North America - GlobeNewsWire